Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Positive results in my view.
Products are selling, increasing reach by opening 10 more walk in clinics by the end of the year, launch of products in Germany coming soon (distribution agreement in place) and a Treat It App all sounds exciting. DYOR
Let's hope Dr Dan Poulter helps this sector now that he has defected to the Labour party...
Very disappointed that it seems there's no plan to launch Eroxon in the US this year. I'm also concerned that the EU patent protection for Eroxon may not be robust for all markets.
I'm out, for now anyway..
His holding before fund raise = 6,603,082 shares
333,333 shares purchased in the fundraise
New total = 6,936,415 shares, 2.2% of the company after fundraising shares admitted on Monday.
No shares sold as far as I can see.
No shares have been sold.
Read the last 2 RNS releases and check the names and numbers for yourself.
UK Customers can now get Eroxon on NHS prescription, so OTC sales may appear to drop but this isn’t likely to be the case. Coopers and Haleon will be able to analyse demand through NHS contracts, which is highly significant in my view.
Dug,
Maybe the company are waiting for the results of this study, link below , before joining the National screening trial.. Make no mistake, I’m massively down on this share and would welcome any positive news!
https://research-portal.uea.ac.uk/en/projects/new-epigenetic-markers-for-prostate-cancer-detection-in-black-men
Dog walker
I don’t think the UK screening trial is a dealbreaker personally.. perhaps it’s not a priority for the company, i.e. to provide free PSE tests in a study when they can sell them via BUPA?
Private health care companies will pay for tests if it'll save money on their overall costs (fewer biopsies). Drs will request a PSE if they're allowed to by the health insurers regardless of the cost.
Also I'd pay for a test rather than go through 16 needles into my prostate under local anesthetic!
I think they definitely need the labs to process the tests, you can't sell a test that you can't send to a lab. There is also a UK study due to complete in the next few months testing PSE in black men. I believe that there will be a high demand for the PSE test when the UK lab is approved (? end of March) especially with established BUPA links but that's just my opinion.
I think they seem to specialise in M & A but do your own research.
Does anyone else think the company is a target for takeover by a large pharma like Pfizer ( Viagra) or Lilly ICOS (Cialis)? Especially before the US launch?
It’s a frequent occurrence for clinical trials to open and then have amendments to include other arms of the trial. Just because PSE isn’t in the first version of the protocol doesn’t mean it won’t be included via an amendment when approved by the governance process (REC ethics committee). Just my opinion.
Is there a buyer in the background, sales should equal buys. A dummy sell lets me sell all my holding, something doesn't add up..
bighammer, you're numbers are wrong - I've cut and paste this for you - from placing RNS 10th Sept 2021 FYI
'The Company estimates that the total addressable UK market is up to £5 million per annum with Europe potentially another £30 million per annum. The Directors believe that the UK and Europe presents an attractive market opportunity for the Company to target. The Company expects to pursue a direct distributor model alongside some investment in its own business development activities including a direct selling and support team of less than eight people which will be complimentary to IHC and help drive initial adoption.
In terms of the US opportunity, that market is estimated to have 900 sites and 500,000 infant intensive care admissions per annum and a market opportunity in excess of £20 million per annum.'
Reality is, GDR have stated income from NHS is £5M (company spends are £5.5-6 M p.a). They need to sell to EU (estimated £30M market to generate profit. Also will need to spend an estimated £2 million to get this test through FDA studies to sell into US.
I'm looking forward to hearing what the CEO presentation next week tells us about H2 plans.
Doc. updated today
https://www.genedrive.com/documents/id-rnr1-ifu-en_v10_genedrive_mt-rnr1_id_kit_instructions_for_use.pdf
Inphobe, I agree. We were told in the last GDR presentation that the PALOH study will be published in a prestigious US pediatric journal. A study author said that it is expected to be published in March (they should know). In my opinion this could be released online any day now. Obviously, NICE will need this publication before releasing their guidance.
GDR website update today, Inspiration Health details added on distributor page for the AIHL test. Hopefully this indicates the product launch will happen soon!
https://www.genedrive.com/distribution/index.php